<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01404156</url>
  </required_header>
  <id_info>
    <org_study_id>CDHA 174431-7</org_study_id>
    <nct_id>NCT01404156</nct_id>
  </id_info>
  <brief_title>Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma</brief_title>
  <acronym>POWERRANGER</acronym>
  <official_title>PreOperative Treatment With chEmotheRapy or chemoRAdiatioN in esophaGeal or gastroEsophageal adenocaRcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Gordon Buduhan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CancerCare Manitoba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CancerCare Manitoba</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The best treatment for resectable esophageal or gastroesophageal adenocarcinoma is unknown.&#xD;
      Although an operation to remove the esophagus is the most common treatment, previous studies&#xD;
      have shown that patients live longer when either perioperative (before and after surgery)&#xD;
      chemotherapy or preoperative (before surgery) chemotherapy plus radiation is given, compared&#xD;
      to surgery alone. However it is unknown which of these treatments (perioperative chemotherapy&#xD;
      or preoperative chemoradiation) is more effective in improving survival. A study where&#xD;
      patients with resectable esophageal / GE junction cancer are chosen at random to receive one&#xD;
      of the two preoperative treatments would help determine if one form of treatment improves&#xD;
      survival compared to the other.&#xD;
&#xD;
      Patients with localized esophageal / GE junction cancer (adenocarcinoma) will be randomized&#xD;
      to receive either preoperative and postoperative chemotherapy or preoperative chemoradiation&#xD;
      followed by surgery.&#xD;
&#xD;
      The main objective of this pilot trial is to determine the possibility of conducting a larger&#xD;
      study with many centers participating. If this study proves to be feasible with enough&#xD;
      patients enrolled and able to tolerate treatments without major side effects then we can&#xD;
      hopefully proceed to perform a larger multi-center trial to look for survival outcome&#xD;
      differences between patients who receive preoperative chemotherapy and those who receive&#xD;
      preoperative chemoradiation. The results of this trial would ultimately help us choose the&#xD;
      most effective treatment of resectable esophageal cancer and hopefully improve survival.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVE To determine the feasibility of a randomized trial of neoadjuvant chemotherapy vs.&#xD;
      neoadjuvant chemoradiation for patients with resectable adenocarcinoma of the esophagus or&#xD;
      gastroesophageal junction.&#xD;
&#xD;
      RESEARCH PLAN Phase III randomized 2-arm parallel group pilot study&#xD;
&#xD;
      1:1 randomization to A) or B)&#xD;
&#xD;
      TREATMENT REGIMEN A) PERIOPERATIVE CHEMOTHERAPY (OPTION of CHEMO REGIMEN 1 or 2) 1) FLOT -&#xD;
      Four x 14 day cycles FLOT preoperatively and 4 cycles postoperatively: 5-Fluorouracil 2600&#xD;
      mg/m², day 1 IV every 14 days Leucovorin 200 mg/m², day 1, IV., every 14 days Oxaliplatin 85&#xD;
      mg/m², day 1, IV, every 14 days Docetaxel 50mg/m2, day 1, IV, every 14 days&#xD;
&#xD;
      OR&#xD;
&#xD;
      2) ECF / ECX - Three x 21-day cycles ECF preoperatively and 3 cycles postoperatively (within&#xD;
      4-10 weeks after surgery): Epirubicin (50 mg/m²,) day 1 IV Cisplatin: 60 mg/m², day 1 IV&#xD;
      5-Fluorouracil: 200 mg/m², daily for 21 days by continuous IV infusion 5-FU may be&#xD;
      substituted with Capecitabine (Xeloda) 625mg/m2, BID (ECX)&#xD;
&#xD;
      OR&#xD;
&#xD;
      B) NEOADJUVANT CHEMORADIATION&#xD;
&#xD;
      1) -carboplatin and paclitaxel given on days 1, 8, 15, 22 and 29&#xD;
&#xD;
        -  paclitaxel: 50 mg / m2 IV&#xD;
&#xD;
        -  carboplatin: dosed to an area under the curve of 2, by Calvert formula Radiation Therapy&#xD;
           45-50.4 Gy in 25-28 fractions of 1.8 Gy/fraction, 5 fractions/wk 45-50.4 Gy in 25-28&#xD;
           fractions of 1.8 Gy/fraction, 5 fractions/wk Upon completion of neoadjuvant therapy, all&#xD;
           patients will be considered for surgery.&#xD;
&#xD;
      Patients will be deemed acceptable for surgery provided:&#xD;
&#xD;
        -  repeat imaging performed after neoadjuvant therapy does not demonstrate distant&#xD;
           metastases or local invasion of the primary tumor into vital structures (heart, great&#xD;
           vessels, trachea)&#xD;
&#xD;
        -  maintenance of adequate performance status and ability to tolerate esophagectomy&#xD;
&#xD;
      Surgery will be performed preferably within 8 weeks of completion of neoadjuvant therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>compliance with assigned neoadjuvant treatment</measure>
    <time_frame>5 weeks for chemoradiation arm, 6-8 weeks for chemotherapy arm</time_frame>
    <description>- &gt;60% patients allocated for randomization will start and complete treatment without major protocol violation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>treatment response</measure>
    <time_frame>5 weeks for chemoradiation arm, 6-8 weeks for chemotherapy arm</time_frame>
    <description>&gt;30% of patients in both treatment arms demonstrate partial or complete response as defined by Mandard TRG 1-3 on pathologic staging</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>survival</measure>
    <time_frame>3 years</time_frame>
    <description>3 year overall- and disease-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC QOL</measure>
    <time_frame>baseline, 3, 6, 9, 12 months post treatment</time_frame>
    <description>European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C-30 Version 3.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Esophageal Cancer</condition>
  <condition>Adenocarcinoma, Esophageal</condition>
  <condition>Adenocarcinoma, Gastroesophageal Junction</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NEOADJUVANT CHEMOTHERAPY (OPTION of CHEMO REGIMEN 1 or 2)&#xD;
1) FLOT - Four x 14 day cycles FLOT preoperatively and 4 cycles postoperatively (within 4-10 weeks after surgery): 5-Fluorouracil 2600 mg/m², day 1 IV every 14 days Leucovorin 200 mg/m², day 1, IV., every 14 days Oxaliplatin 85 mg/m², day 1, IV, every 14 days Docetaxel 50mg/m2, day 1, IV, every 14 days&#xD;
2) ECF / ECX - Three x 21-day cycles ECF preoperatively and 3 cycles postoperatively (within 4-10 weeks after surgery): Epirubicin (50 mg/m²,mg per square meter of body-surface area) by intravenous bolus on day 1 IV Cisplatin: 60 mg/m², mg per square meter intravenously with hydration on day 1 IV 5-Fluorouracil: 200 mg/m², mg per square meter daily for 21 days by continuous intravenous infusionIV infusion 5-FU may be substituted with Capecitabine (Xeloda) 625mg/m2 PO BID (ECX)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoadjuvant Chemoradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1) -carboplatin and paclitaxel given on days 1, 8, 15, 22 and 29&#xD;
paclitaxel: 50 mg / m2 IV over 1 hour&#xD;
carboplatin: dosed to an area under the curve of 2, by Calvert formula, as a 1 hour IV infusion Radiation Therapy Concurrent radiation therapy will begin within 24 hours of initiation of chemotherapy for patients randomized to chemoradiation treatment.&#xD;
Dose specifications:&#xD;
Phase 1: Total radiation prescription dose 45 Gy given in 25 fractions of 1.8 Gy per fraction, 5 fractions / week, one treatment / day, starting on the first day of first cycle of chemotherapy.&#xD;
Phase 2: (GTV only) Boost is not mandatory and up to the discretion of radiation oncologist. Total radiation prescription dose 5.4 Gy given in 3 fractions of 1.8 Gy per fraction, 5 fractions / week, one treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(Epirubicin Cisplatin 5-Fluorouracil / Xeloda) OR 5-Fluorouracil Leucovorin Oxaliplatin Docetaxel</intervention_name>
    <description>NEOADJUVANT CHEMOTHERAPY (OPTION of CHEMO REGIMEN 1 or 2)&#xD;
1) FLOT - Four x 14 day cycles FLOT preoperatively and 4 cycles postoperatively (within 4-10 weeks after surgery): 5-Fluorouracil 2600 mg/m², day 1 IV every 14 days Leucovorin 200 mg/m², day 1, IV., every 14 days Oxaliplatin 85 mg/m², day 1, IV, every 14 days Docetaxel 50mg/m2, day 1, IV, every 14 days&#xD;
2) ECF / ECX - Three x 21-day cycles ECF preoperatively and 3 cycles postoperatively (within 4-10 weeks after surgery): Epirubicin (50 mg/m²,mg per square meter of body-surface area) by intravenous bolus on day 1 IV Cisplatin: 60 mg/m², mg per square meter intravenously with hydration on day 1 IV 5-Fluorouracil: 200 mg/m², mg per square meter daily for 21 days by continuous IV infusion 5-FU may be substituted with Capecitabine (Xeloda) 625mg/m2, PO BID (ECX)</description>
    <arm_group_label>Neoadjuvant Chemotherapy</arm_group_label>
    <other_name>ECF/ECX or FLOT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Carboplatin paclitaxel plus concurrent radiotherapy</intervention_name>
    <description>5 cycles carboplatin and paclitaxel given on days 1, 8, 15, 22 and 29 preoperatively:&#xD;
paclitaxel: 50 mg / m2 IV over 1 hour&#xD;
carboplatin: dosed to an area under the curve of 2, by Calvert formula, as a 1 hour IV infusion&#xD;
Radiation Therapy Concurrent radiation therapy will begin within 24 hours of initiation of chemotherapy for patients randomized to chemoradiation treatment.&#xD;
1. Dose specifications:&#xD;
Phase 1: Total radiation prescription dose 45 Gy given in 25 fractions of 1.8 Gy per fraction, 5 fractions / week, one treatment / day, starting on the first day of first cycle of chemotherapy. This total radiation dose option is acceptable if boost dose is not possible due to clinical reasons or dosimetric constraints.&#xD;
Phase 2: (GTV only) Boost is not mandatory and up to the discretion of radiation oncologist. Total radiation prescription dose 5.4 Gy given in 3 fractions of 1.8 Gy per fraction, 5 fractions / week, one treatment .</description>
    <arm_group_label>Neoadjuvant Chemoradiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adenocarcinoma of esophagus or gastroesophageal junction; -cT1N1-3 or T2-4Nx; M0 by&#xD;
             American Joint Committee on Cancer (AJCC) 7th Edition staging classification&#xD;
&#xD;
          -  proximal portion of the tumor at least 20 cm from the incisors on endoscopy, and&#xD;
             extend no greater than 2 cm into the gastric cardia&#xD;
&#xD;
          -  tumor length &lt; 8cm; diameter &lt; 5 cm&#xD;
&#xD;
          -  age &gt; 18 years&#xD;
&#xD;
          -  absolute neutrophil count (ANC) ≥ 1.5 x 109 / L&#xD;
&#xD;
          -  platelet count &gt; 100 x 109 / L&#xD;
&#xD;
          -  creatinine clearance &gt; 50 ml / min&#xD;
&#xD;
          -  bilirubin &lt; 1.5x upper limit normal&#xD;
&#xD;
          -  FEV1 &gt; 1.0 L&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  positive serum / urine pregnancy test for females of childbearing age&#xD;
&#xD;
          -  previous primary / recurrent malignancy in last 5 years (history of previous / current&#xD;
             non-melanoma skin cancer or cervical in-situ carcinoma in last 5 years acceptable for&#xD;
             inclusion in trial)&#xD;
&#xD;
          -  previous chemotherapy for esophageal cancer&#xD;
&#xD;
          -  previous radiation therapy that would overlap required radiation fields&#xD;
&#xD;
          -  major systemic illness(es) that would limit life expectancy &lt;2 years&#xD;
&#xD;
          -  psychiatric / cognitive illness that would limit ability to give informed consent&#xD;
&#xD;
          -  (Patients will be reviewed by both a medical and radiation oncologist and deemed fit&#xD;
             to undergo either neoadjuvant chemotherapy or chemoradiation, respectively)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gordon Buduhan, MD MSc FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Manitoba / CancerCare Manitoba</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gordon Buduhan, MD MSc FRCSC</last_name>
    <phone>204-787-3109</phone>
    <email>gbuduhan@exchange.hsc.mb.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kathi Klapp</last_name>
    <phone>204-787-2159</phone>
    <email>kathi.klapp@cancercare.mb.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Health Sciences Centre / CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deb Lewis</last_name>
      <phone>519-685-8500</phone>
      <phone_ext>75685</phone_ext>
      <email>deb.lewis@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Richard Malthaner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital / Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Lister</last_name>
      <email>Jennifer.Lister@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Gail Darling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 26, 2011</study_first_submitted>
  <study_first_submitted_qc>July 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2011</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>CancerCare Manitoba</investigator_affiliation>
    <investigator_full_name>Dr. Gordon Buduhan</investigator_full_name>
    <investigator_title>MD MSc FRCSC Assistant Professor of Surgery Section of Thoracic Surgery,</investigator_title>
  </responsible_party>
  <keyword>Esophageal cancer</keyword>
  <keyword>Neoadjuvant</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Chemoradiation</keyword>
  <keyword>Surgery</keyword>
  <keyword>Esophagectomy</keyword>
  <keyword>Adenocarcinoma</keyword>
  <keyword>Gastroesophageal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

